欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (2): 215-218.

• 研究原著 • 上一篇    下一篇

主动免疫联合烯丙雌醇治疗原因不明反复自发性流产的临床疗效评估

徐岚, 郑燕銮, 张新能   

  1. 汕头大学医学院第一附属医院妇产科, 汕头515041, 广东
  • 收稿日期:2004-12-15 修回日期:2005-01-25 出版日期:2005-02-06 发布日期:2020-11-18
  • 通讯作者: 徐岚, 女, 博士, 副主任医师, 主要从事临床生殖医学研究。Tel:0754-8877917 E-mail:xulandoctor@163.com

Evaluation of clinical efficacy of combination of active immunotherapy and allylestrenol in treatment of patients with unexplained recurrent spontaneous abortion

XU Lan, ZHEN Yan-luan, ZHANG Xin-neng   

  1. Department of Obstetrics and Gynecology, the First Affiliated Hospital of Medical College, Shantou University, Shantou 515041, Guangdong, China
  • Received:2004-12-15 Revised:2005-01-25 Online:2005-02-06 Published:2020-11-18

摘要: 目的:评价主动免疫联合烯丙雌醇(allylestrenol)治疗原因不明反复自发性流产(URSA) 的临床疗效, 为临床原因不明反复自发性流产的治疗寻求最佳方案。方法:435 例原发性原因不明反复自发性流产患者分为3 组。联合治疗组185 例, 接受主动免疫联合烯丙雌醇治疗;主动免疫组152 例, 单纯接受主动免疫治疗;烯丙雌醇组98 例, 只接受烯丙雌醇治疗;另有96 例继发性原因不明反复性流产患者, 为继发URSA 组, 全部接受主动免疫联合烯丙雌醇治疗。结果:联合治疗组妊娠成功率为92.05%,主动免疫组为71.43%, 烯丙雌醇组为31.51%, 继发URSA 组为86.76%(P<0.01) 。联合治疗对原发和继发URSA 的疗效相近(P>0.05) 。结论:在本研究中主动免疫联合烯丙雌醇治疗原因不明反复自发性流产疗效最好, 值得在临床推广应用。

关键词: 免疫治疗, 反复自发性流产, 烯丙雌醇, 临床试验, 疗效

Abstract: AIM: To evaluate the clinical efficacy of combination of active immunotherapy and allylestrenol in treatment of patients with unexplained recurrent spontaneous abortion (URSA) and to investigate a best therapeutic method in treatment of patients with URSA.METHODS: 435 patients with primary URSA were randomly assigned to three groups:185 in combination medication group which was treated with active immunotherapy and allylestrenol, 152 in active immunotherapy group which was only treated with active immunotherapy, 98 in allylestrenol group which was only treated with allylestrenol. 96 secondary URSA in secondary URSA group were treated with active immunotherapy and allylestrenol.RESULTS: The successful pregnant rates of combination medication group, active immunotherapy group, allylestrenol group and secondary group were 92.05%, 71.43%, 31.51%and 86.76%, respectively.The successful pregnant rate in combination group were higher than that in the active immunotherapy group and the allylestrenol group (P<0.01), but there was no significant difference between combination group and the secondary URSA group (P> 0.05).CONCLUSION: Combination of active immunotherapy and allylestrenol is better than other therapy method in treatment of patients with URSA, which is worth further widespread application in clinical practice.

Key words: immunotherapy, recurrent spontaneous abortion, allylestrenol, clinical trial, efficacy

中图分类号: